Number of suitable clients: CDEC reviewed the uncertainty in the quantity of individuals with moderately intense to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some people that are classified as having delicate or average disease could have a significant bleeding phenotype, https://albertb578wyz2.blogdomago.com/profile